People In Health Care
Dr Marina Berbic
Genetic Pathologist and Deputy Director of Genetics
Douglass Hanly Moir Pathology
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
Australian Health Journal spoke to Dr Berbic about her career and being a genetic pathologist. She started as a junior doctor in obstetrics and gynaecology after completing a medical degree, though never thought about specialising in pathology. The more she learned about genetic pathology, the more intrigued she became, realising that this specialty aligned with both her strengths and interests.
Dr Berbic has always been interested in science, technology, and innovation. She first studied for a Bachelor of Medical Science degree, followed by a Master’s in Reproductive Health and Human Genetics and then a PhD in Reproductive Medicine. Dr Berbic has long-standing academic interests, both from a research and teaching perspective. She continues to be involved in medical education at the University of New South Wales in her role as an Adjunct Senior Lecturer.
After completing her specialist training and attaining fellowship of the Royal College of Pathologists of Australasia, she commenced her role as a genetic pathologist at Douglass Hanly Moir and later became the Deputy Director of Genetics department. Her role involves providing clinical governance and medical leadership that governs all aspects of medical testing in genetics.
In this interview, Dr Berbic talks about the exciting area of genetic pathology impacting multiple areas of medicine including paediatrics, obstetrics and gynaecology, cardiology, neurology, oncology, and other fields.
The results of genetic testing have a potential impact on the patient’s diagnosis, the decisions that couples may take when they’re making reproductive decisions, and also have predictive implications. The testing results may influence therapy, selection, or patient management and may have far ranging impact on the individual as well as their family.
-
Being Part of the New Health Frontier
In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
